At the same time, this similarity of secondary cases to their de novo counterparts, suggests that paired analysis of secondary stage IV tumors comparative to their earlier stage ancestors represents a promising approach to decipher the molecular pathogenesis of metastatic EGFR+ lung cancer in general. The gene discussed is EGFR; the disease is lung carcinoma.